Avondale Wealth Management’s DexCom DXCM Stock Holding History

Avondale Wealth Management’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-60	Closed	-$8K	–	120
2022 Q1	$8K	Buy	+60	New	+$6.56K	0.01%	100

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Avondale Wealth Management's DXCM Position: Q2 2022 in Review

Avondale Wealth Management sold out of DexCom (DXCM) in Q2 2022, closing a stake of 60 shares — an estimated $8K sold.

Avondale Wealth Management first reported a position in DXCM in Q1 2022 and held it in 1 quarter. The position peaked at $8K in Q1 2022. 797 funds tracked by Wall St. Rank hold DXCM as of Q2 2022.

Avondale Wealth Management reported no remaining DexCom position as of Q2 2022 after selling out during the quarter.
Avondale Wealth Management sold 60 DexCom shares in Q2 2022, an estimated $8K.
Avondale Wealth Management first reported a position in DexCom in Q1 2022 and held it in 1 quarter.
Avondale Wealth Management's DexCom position peaked at $8K in Q1 2022.
797 funds tracked by Wall St. Rank held DexCom as of Q2 2022.

Based on Avondale Wealth Management's 13F filing for Q2 2022, filed 11 Jul 2022.